

PATIENT ALERT CARD

Please carry this card with you at all times and show it to any healthcare professional to inform them about your current treatment with CERDELGA.

- Do not start any new prescription medication, over-the-counter medication or herbal product without telling your doctor or pharmacist¹
- Do not consume grapefruit or grapefruit products¹

sanofi

Patient's name:

Date CERDELGA first prescribed:

Centre name:

Treating doctor's name:

Treating doctor's phone number:

CYP2D6 Metaboliser Status:

- Poor Metaboliser Intermediate Metaboliser Extensive Metaboliser

Information for healthcare professionals²

CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1).
For additional information, please refer to the full Product Information or contact Medical Information (1800 818 806 or Medinfo.australia@sanofi.com)

Extensive Metaboliser (EM) and Intermediate Metaboliser (IM) patients:

- CERDELGA must not be used in EM and IM patients:
 - taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor
- CERDELGA must not be used in EM or IM patients with any degree of hepatic impairment except in EM patients with mild hepatic impairment not being treated with a strong or moderate CYP2D6 inhibitor
- CERDELGA is not recommended to be used:
 - in EM or IM patients with end stage renal disease or in IM patients with mild, moderate or severe renal impairment
 - in combination with strong CYP3A inducers
- CERDELGA should be used with caution in combination with:
 - a moderate CYP2D6 inhibitor
 - a strong or moderate CYP3A inhibitor
 - a P-glycoprotein (P-gp) or a CYP2D6 substrate (lower doses of such drugs may be required)
- CERDELGA dose should be reduced to 84 mg ONCE a day:
 - in EM or IM patients when concomitantly treated with a strong CYP2D6 inhibitor
 - in EM patients with mild hepatic impairment treated with a weak CYP2D6 inhibitor or any CYP3A inhibitor

Poor Metaboliser (PM) patients:

- CERDELGA must not be used:
 - in combination with a strong CYP3A inhibitor
 - in PM patients with any degree of hepatic impairment
- CERDELGA is not recommended to be used:
 - in combination with a moderate CYP3A inhibitor or a strong CYP3A inducer
 - in PM patients with end stage renal disease or in PM patients with mild, moderate or severe renal impairment
- CERDELGA should be used with caution in combination with:
 - a weak CYP3A inhibitor
 - a P-gp or a CYP2D6 substrate (lower doses of such drugs may be required)

REFERENCES: 1. Cerdelga Consumer Medicine Information. 2. Cerdelga Product Information.

Cerdelga[®] is a registered trademark of Sanofi. sanofi-aventis australia pty ltd trading as Sanofi ABN 31 008 558 807. Sydney, Australia. MAT-AU-2600225. Date of preparation February 2026.